• Explore /
  • Poster
  • / A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186—Trials in progress.

A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186—Trials in progress.

Abstract Poster

Authors

null

Efrat Dotan

Fox Chase Cancer Center, Philadelphia, PA

Efrat Dotan , Paul J. Catalano , Leon Lenchik , Robert Boutin , Xin Yao , Shaalan Shaalan Beg , Namrata Vijayvergia , Constantine Gatsonis , David Bing Zhen , Daneng Li , Lynne I. Wagner , Melissa A. Simon , Terence Z. Wong , Peter J. O'Dwyer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT04233866

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4185)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4185

Abstract #

TPS4185

Poster Bd #

157b

Abstract Disclosures

Similar Posters

First Author: Benedikt Westphalen

First Author: Gulam Abbas Manji

First Author: Gabriela Dieguez

First Author: Brett A. Schroeder